RS66096B1 - Upotreba sepiapterina i njegovih metabolita za tretiranje izlaganja zračenju - Google Patents
Upotreba sepiapterina i njegovih metabolita za tretiranje izlaganja zračenjuInfo
- Publication number
- RS66096B1 RS66096B1 RS20241189A RSP20241189A RS66096B1 RS 66096 B1 RS66096 B1 RS 66096B1 RS 20241189 A RS20241189 A RS 20241189A RS P20241189 A RSP20241189 A RS P20241189A RS 66096 B1 RS66096 B1 RS 66096B1
- Authority
- RS
- Serbia
- Prior art keywords
- mir
- sepiapterin
- patient
- pharmaceutically acceptable
- crystal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962882937P | 2019-08-05 | 2019-08-05 | |
| EP20758407.9A EP4009978B1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| PCT/US2020/045026 WO2021026247A1 (en) | 2019-08-05 | 2020-08-05 | Use of sepiapterin and metabolites thereof to treat radiation exposure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66096B1 true RS66096B1 (sr) | 2024-11-29 |
Family
ID=72148243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241189A RS66096B1 (sr) | 2019-08-05 | 2020-08-05 | Upotreba sepiapterina i njegovih metabolita za tretiranje izlaganja zračenju |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220273661A1 (https=) |
| EP (2) | EP4454712A3 (https=) |
| JP (2) | JP7642611B2 (https=) |
| CN (2) | CN114555090B (https=) |
| AU (1) | AU2020324435B2 (https=) |
| BR (1) | BR112022002029A2 (https=) |
| CA (1) | CA3146477A1 (https=) |
| DK (1) | DK4009978T3 (https=) |
| ES (1) | ES2994060T3 (https=) |
| FI (1) | FI4009978T3 (https=) |
| HR (1) | HRP20241653T1 (https=) |
| HU (1) | HUE069012T2 (https=) |
| IL (1) | IL290321B1 (https=) |
| LT (1) | LT4009978T (https=) |
| MX (1) | MX2022001535A (https=) |
| PL (1) | PL4009978T3 (https=) |
| PT (1) | PT4009978T (https=) |
| RS (1) | RS66096B1 (https=) |
| SI (1) | SI4009978T1 (https=) |
| SM (1) | SMT202500089T1 (https=) |
| WO (1) | WO2021026247A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| WO2005048926A2 (en) | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| TWI359019B (en) * | 2006-08-14 | 2012-03-01 | Merck Eprova Ag | Use of folates for the prevention and treatment of |
| MX379061B (es) | 2013-09-13 | 2025-03-04 | Bioventures Llc | Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion. |
| CN106794197A (zh) | 2014-10-02 | 2017-05-31 | 西托索尔本茨公司 | 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途 |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) * | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| CN110354133A (zh) * | 2019-08-26 | 2019-10-22 | 鞍山市肿瘤医院 | 四氢生物蝶呤的应用及药物 |
-
2020
- 2020-08-04 IL IL290321A patent/IL290321B1/en unknown
- 2020-08-05 AU AU2020324435A patent/AU2020324435B2/en active Active
- 2020-08-05 CN CN202080069308.5A patent/CN114555090B/zh active Active
- 2020-08-05 BR BR112022002029A patent/BR112022002029A2/pt unknown
- 2020-08-05 CA CA3146477A patent/CA3146477A1/en active Pending
- 2020-08-05 LT LTEPPCT/US2020/045026T patent/LT4009978T/lt unknown
- 2020-08-05 DK DK20758407.9T patent/DK4009978T3/da active
- 2020-08-05 PL PL20758407.9T patent/PL4009978T3/pl unknown
- 2020-08-05 MX MX2022001535A patent/MX2022001535A/es unknown
- 2020-08-05 SM SM20250089T patent/SMT202500089T1/it unknown
- 2020-08-05 JP JP2022507561A patent/JP7642611B2/ja active Active
- 2020-08-05 CN CN202411691224.1A patent/CN119837879A/zh active Pending
- 2020-08-05 HR HRP20241653TT patent/HRP20241653T1/hr unknown
- 2020-08-05 WO PCT/US2020/045026 patent/WO2021026247A1/en not_active Ceased
- 2020-08-05 RS RS20241189A patent/RS66096B1/sr unknown
- 2020-08-05 EP EP24187395.9A patent/EP4454712A3/en active Pending
- 2020-08-05 SI SI202030521T patent/SI4009978T1/sl unknown
- 2020-08-05 US US17/631,995 patent/US20220273661A1/en active Pending
- 2020-08-05 EP EP20758407.9A patent/EP4009978B1/en active Active
- 2020-08-05 PT PT207584079T patent/PT4009978T/pt unknown
- 2020-08-05 HU HUE20758407A patent/HUE069012T2/hu unknown
- 2020-08-05 FI FIEP20758407.9T patent/FI4009978T3/fi active
- 2020-08-05 ES ES20758407T patent/ES2994060T3/es active Active
-
2025
- 2025-02-26 JP JP2025029508A patent/JP2025098011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114555090A (zh) | 2022-05-27 |
| US20220273661A1 (en) | 2022-09-01 |
| EP4454712A3 (en) | 2025-01-01 |
| FI4009978T3 (fi) | 2024-11-01 |
| JP2025098011A (ja) | 2025-07-01 |
| EP4009978A1 (en) | 2022-06-15 |
| HUE069012T2 (hu) | 2025-02-28 |
| EP4009978B1 (en) | 2024-09-25 |
| ES2994060T3 (en) | 2025-01-16 |
| CN119837879A (zh) | 2025-04-18 |
| SI4009978T1 (sl) | 2025-03-31 |
| BR112022002029A2 (pt) | 2022-06-07 |
| CA3146477A1 (en) | 2021-02-11 |
| AU2020324435A1 (en) | 2022-02-24 |
| JP2022543655A (ja) | 2022-10-13 |
| IL290321B1 (en) | 2026-04-01 |
| LT4009978T (lt) | 2024-11-25 |
| HRP20241653T1 (hr) | 2025-04-25 |
| PL4009978T3 (pl) | 2025-02-24 |
| PT4009978T (pt) | 2024-11-05 |
| WO2021026247A1 (en) | 2021-02-11 |
| IL290321A (en) | 2022-04-01 |
| CN114555090B (zh) | 2024-12-17 |
| JP7642611B2 (ja) | 2025-03-10 |
| MX2022001535A (es) | 2022-03-04 |
| AU2020324435B2 (en) | 2026-03-19 |
| DK4009978T3 (da) | 2024-10-14 |
| SMT202500089T1 (it) | 2025-03-12 |
| EP4454712A2 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020324435B2 (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| EP3054952B1 (en) | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer | |
| Yang et al. | Lipoxin A4 restores oxidative stress-induced vascular endothelial cell injury and thrombosis-related factor expression by its receptor-mediated activation of Nrf2-HO-1 axis | |
| Wang et al. | The roles of oxidative stress and Beclin-1 in the autophagosome clearance impairment triggered by cardiac arrest | |
| US20090035292A1 (en) | Use of phosphatases to treat neuroblastomas and medulloblastomas | |
| JP2017078056A (ja) | 有機セレン化合物の組成物およびその使用方法 | |
| US20090318534A1 (en) | Methods and compositions for the treatment of skin diseases and disorders | |
| JP3041232B2 (ja) | 癌転移抑制剤 | |
| CN115605201A (zh) | 血管紧张素ii 2型受体激动剂的新用途 | |
| WO2017136515A1 (en) | Chemicals and methods to prevent and treat tgf-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis | |
| WO2020110089A1 (en) | Urolithin a and a composition containing same for external use in inflammations of various etiologies | |
| RS52737B (sr) | Roscovitine za lečenje izvesnih cističnih bolesti | |
| TW201609094A (zh) | 治療癌症之新穎方法 | |
| CN113286587A (zh) | 用于治疗iv型胶原病的联苯磺酰胺化合物 | |
| WO2021262799A1 (en) | Anti-viral compounds and methods of using same | |
| JP2015534942A (ja) | Ｃｂｐ／カテニン阻害剤を用いる過剰増殖性及び前がん性皮膚病の治療 | |
| HK40118407A (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| HK40075560A (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| HK40075560B (en) | Use of sepiapterin and metabolites thereof to treat radiation exposure | |
| EA048135B1 (ru) | Применение сепиаптерина и его метаболитов для лечения радиационного облучения | |
| EA052521B1 (ru) | Применение сепиаптерина и его метаболитов для лечения радиационного облучения | |
| JP7511741B2 (ja) | ２，３，５－置換されたチオフェン化合物の胃腸管間質腫瘍の予防、改善または治療用途 | |
| WO2018140586A1 (en) | Use of ape/ref-1 redox specific inhibitors for treating metastatic prostate cancer | |
| EP4495238A2 (en) | Targeting egln1 in cancer | |
| EP4545076A1 (en) | Lat1 selective inhibitors for use in the treatment of adverse ventricular -remodelling and of heart failure |